CIMT 2021: report on the 18th Annual Meeting of the Association for Cancer Immunotherapy

References

• Martínez Bedoya D, Dutoit V, Migliorini D. Allogeneic CAR T cells: an alternative to overcome challenges of CAR T cell therapy in glioblastoma. Front Immunol. 2021;12:640082. eng. doi:10.3389/fimmu.2021.640082.
   PubMed Web of Science ®Google Scholar
• Stenger D, Stief TA, Kaeuferle T, Willier S, Rataj F, Schober K, Vick B, Lotfi R, Wagner B, Grünewald TGP, et al. Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR. Blood. 2020;136(12):1407–10. eng. doi:10.1182/blood.2020005185.
   PubMed Web of Science ®Google Scholar
• Qasim W, Zhan H, Samarasinghe S, Adams S, Amrolia P, Stafford S, Butler K, Rivat C, Wright G, Somana K, et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med. 2017;9(374). eng. doi:10.1126/scitranslmed.aaj2013.
   PubMed Web of Science ®Google Scholar
• Jahn L, Hombrink P, Hagedoorn RS, Kester MGD, van der Steen DM, Rodriguez T, Pentcheva-Hoang T, de Ru AH, Schoonakker MP, Meeuwsen MH, et al. TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1. Blood. 2017;129(10):1284–1295. eng. doi:10.1182/blood-2016-09-737536.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21–33. eng. doi:10.4065/78.1.21.
   PubMed Web of Science ®Google Scholar
• Chan CJ, Smyth MJ, Martinet L. Molecular mechanisms of natural killer cell activation in response to cellular stress. Cell Death Differ. 2014;21(1):5–14. eng. doi:10.1038/cdd.2013.26.
   PubMed Web of Science ®Google Scholar
• Kumari S, Wälchli S, Fallang L-E, Yang W, Lund-Johansen F, Schumacher TN, Olweus J. Alloreactive cytotoxic T cells provide means to decipher the immunopeptidome and reveal a plethora of tumor-associated self-epitopes. Proc Natl Acad Sci U S A. 2014;111(1):403–408. eng. doi:10.1073/pnas.1306549111.
   PubMed Web of Science ®Google Scholar
• Ali M, Giannakopoulou E, Li Y, Lehander M, Virding Culleton S, Yang W, Knetter C, Can Odabasi M, Bollineni RC, Yang X, et al. T cells targeted to TdT kill leukemic lymphoblasts while sparing normal lymphocytes. Nat Biotechnol doi:10.1038/s41587-021-01089-x. 2021. eng.
   PubMed Web of Science ®Google Scholar
• Bartok O, Pataskar A, Nagel R, Laos M, Goldfarb E, Hayoun D, Levy R, Körner P-R, Kreuger IZM, Champagne J, et al. Anti-tumour immunity induces aberrant peptide presentation in melanoma. Nature. 2021;590(7845):332–337. eng. doi:10.1038/s41586-020-03054-1.
   PubMedGoogle Scholar
• Kalaora S, Nagler A, Nejman D, Alon M, Barbolin C, Barnea E, Ketelaars SLC, Cheng K, Vervier K, Shental N, et al. Identification of bacteria-derived HLA-bound peptides in melanoma. Nature. 2021;592(7852):138–143. eng. doi:10.1038/s41586-021-03368-8.
   PubMed Web of Science ®Google Scholar
• Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, Franci C, Cheung TK, Fritsche J, Weinschenk T, et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature. 2014;515(7528):572–576. eng. doi:10.1038/nature14001.
   PubMed Web of Science ®Google Scholar
• Lynn GM, Sedlik C, Baharom F, Zhu Y, Ramirez-Valdez RA, Coble VL, Tobin K, Nichols SR, Itzkowitz Y, Zaidi N, et al. Peptide-TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens. Nat Biotechnol. 2020;38(3):320–332. eng. doi:10.1038/s41587-019-0390-x.
   PubMed Web of Science ®Google Scholar
• Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217–21. eng. doi:10.1038/nature22991.
   PubMed Web of Science ®Google Scholar
• Hu Z, Leet DE, Allesøe RL, Oliveira G, Li S, Luoma AM, Liu J, Forman J, Huang T, Iorgulescu JB, et al. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat Med. 2021;27(3):515–525. eng. doi:10.1038/s41591-020-01206-4.
   PubMed Web of Science ®Google Scholar
• Grint DJ, Wing K, Williamson E, McDonald HI, Bhaskaran K, Evans D, Evans SJ, Walker AJ, Hickman G, Nightingale E, et al. Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in England, 16 November to 5 February. Euro Surveill. 2021;26(11). eng. doi:10.2807/1560-7917.ES.2021.26.11.2100256.
   PubMedGoogle Scholar
• Davies NG, Jarvis CI, Edmunds WJ, Jewell NP, Diaz-Ordaz K, Keogh RH. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature. 2021;593(7858):270–74. eng. doi:10.1099/mgen.0.000093.
   PubMed Web of Science ®Google Scholar
• Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ. 2021;372:n579. eng. doi:10.1136/bmj.n579.
   PubMed Web of Science ®Google Scholar
• Bager P, Wohlfahrt J, Fonager J, Albertsen M, Yssing Michaelsen T, Holten Møller C, Ethelberg S, Legarth R, Fischer Button MS, Gubbels SM, et al. Increased risk of hospitalisation associated with infection with SARS-CoV-2 Lineage B.1.1.7 in Denmark. SSRN J. 2021. doi:10.2139/ssrn.3792894.
   Google Scholar
• Brown JC, Goldhill DH, Zhou J, Peacock TP, Frise R, Goonawardane N, Baillon L, Kugathasan R, Pinto AL, McKay PF, et al. Increased transmission of SARS-CoV-2 lineage B.1.1.7 (VOC 2020212/01) is not accounted for by a replicative advantage in primary airway cells or antibody escape. Cold Spring Harbor Laboratory; 2021. doi:10.1101/2021.02.24.432576.
   Google Scholar
• Kissler SM, Fauver JR, Mack C, Tai CG, Breban MI, Watkins AE, Samant RM, Anderson DJ, Ho DD, Metti J, et al. Viral dynamics of SARS-CoV-2 variants in vaccinated and unvaccinated individuals (: medRxiv) doi:10.1101/2021.02.16.21251535. 2021.
   Google Scholar
• Lamers MM, Breugem TI, Mykytyn AZ, Wang Y, Groen N, Knoops K, Schipper D, van der Vaart J, Koopman CD, Zhang J, et al. Human organoid systems reveal in vitro correlates of fitness for SARS-CoV-2 B.1.1.7. Cold Spring Harbor Laboratory; 2021. doi:10.1101/2021.05.03.441080.
   Google Scholar
• He Z, Ren L, Yang J, Guo L, Feng L, Ma C, Wang X, Leng Z, Tong X, Zhou W, et al. Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study. Lancet. 2021;397(10279):1075–84. eng. doi:10.1016/S0140-6736(21)00238-5.
   PubMed Web of Science ®Google Scholar
• Murhekar MV, Bhatnagar T, Thangaraj JWV, Saravanakumar V, Kumar MS, Selvaraju S, Rade K, Kumar CPG, Sabarinathan R, Turuk A, et al. SARS-CoV-2 seroprevalence among the general population and healthcare workers in India, December 2020-January 2021. Int J Infect Dis. 2021;108:145–55. eng. doi:10.1016/j.ijid.2021.05.040.
   PubMed Web of Science ®Google Scholar
• Yadav PD, Sapkal GN, Abraham P, Ella R, Deshpande G, Patil DY, Nyayanit DA, Gupta N, Sahay RR, Shete AM, et al. Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees. Clin Infect Dis. 2021. eng. doi:10.1093/cid/ciab411.
   Web of Science ®Google Scholar
• Liu Y, Liu J, Xia H, Zhang X, Zou J, Fontes-Garfias CR, Weaver SC, Swanson KA, Cai H, Sarkar R, et al. BNT162b2-elicited neutralization against new SARS-CoV-2 Spike variants. N Engl J Med. 2021. eng. doi:10.1056/NEJMc2106083.
   Web of Science ®Google Scholar
• Tarke A, Sidney J, Methot N, Zhang Y, Dan JM, Goodwin B, Rubiro P, Sutherland A, da Silva Antunes R, Frazier A, et al. Negligible impact of SARS-CoV-2 variants on CD4 + and CD8 + T cell reactivity in COVID-19 exposed donors and vaccinees. bioRxiv. 2021. eng. doi:10.1101/2021.02.27.433180.
   PubMedGoogle Scholar
• Monteil V, Kwon H, Prado P, Hagelkrüys A, Wimmer RA, Stahl M, Leopoldi A, Garreta E, Hurtado Del Pozo C, Prosper F, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020;181(4):905–913.e7. eng. doi:10.1016/j.cell.2020.04.004.
   PubMed Web of Science ®Google Scholar
• Monteil V, Dyczynski M, Lauschke VM, Kwon H, Wirnsberger G, Youhanna S, Zhang H, Slutsky AS, Hurtado Del Pozo C, Horn M, et al. Human soluble ACE2 improves the effect of remdesivir in SARS-CoV-2 infection. EMBO Mol Med. 2021;13(1):e13426. eng. doi:10.15252/emmm.202013426.
   PubMed Web of Science ®Google Scholar
• Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med. 1996;184(2):465–72. eng. doi:10.1084/jem.184.2.465.
   PubMed Web of Science ®Google Scholar
• Kreiter S, Selmi A, Diken M, Koslowski M, Britten CM, Huber C, Türeci O, Sahin U. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res. 2010;70(22):9031–40. eng. doi:10.1158/0008-5472.CAN-10-0699.
   PubMed Web of Science ®Google Scholar
• Kranz LM, Diken M, Haas H, Kreiter S, Loquai C, Reuter KC, Meng M, Fritz D, Vascotto F, Hefesha H, et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 2016;534(7607):396–401. eng. doi:10.1038/nature18300.
   PubMed Web of Science ®Google Scholar
• Holtkamp S, Kreiter S, Selmi A, Simon P, Koslowski M, Huber C, Türeci O, Sahin U. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood. 2006;108(13):4009–17. eng. doi:10.1182/blood-2006-04-015024.
   PubMed Web of Science ®Google Scholar
• Kreiter S, Selmi A, Diken M, Sebastian M, Osterloh P, Schild H, Huber C, Türeci O, Sahin U. Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals. J Immunol. 2008;180(1):309–18. eng. doi:10.4049/jimmunol.180.1.309.
   PubMed Web of Science ®Google Scholar
• Karikó K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, Weissman D. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008;16(11):1833–40. eng. doi:10.1038/mt.2008.200.
   PubMed Web of Science ®Google Scholar
• Karikó K, Muramatsu H, Ludwig J, Weissman D. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res. 2011;39(21):e142. eng. doi:10.1093/nar/gkr695.
   PubMed Web of Science ®Google Scholar
• Sahin U, Oehm P, Derhovanessian E, Jabulowsky RA, Vormehr M, Gold M, Maurus D, Schwarck-Kokarakis D, Kuhn AN, Omokoko T, et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 2020;585(7823):107–12. eng. doi:10.1038/nature23306.
   PubMed Web of Science ®Google Scholar
• Reinhard K, Rengstl B, Oehm P, Michel K, Billmeier A, Hayduk N, Klein O, Kuna K, Ouchan Y, Wöll S, et al. An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors. Science. 2020;367(6476):446–53. eng. doi:10.1126/science.aay5967.
   PubMed Web of Science ®Google Scholar
• Sahin U, Derhovanessian E, Miller M, Kloke B-P, Simon P, Löwer M, Bukur V, Tadmor AD, Luxemburger U, Schrörs B, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547(7662):222–26. eng. doi:10.1038/nature23003.
   PubMed Web of Science ®Google Scholar
• Krienke C, Kolb L, Diken E, Streuber M, Kirchhoff S, Bukur T, Akilli-Öztürk Ö, Kranz LM, Berger H, Petschenka J, et al. A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. Science. 2021;371(6525):145–53. eng. doi:10.1126/science.aay3638.
   PubMed Web of Science ®Google Scholar
• Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Raabe V, Bailey R, Swanson KA, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586(7830):589–93. eng. doi:10.1038/s41467-020-17892-0.
   PubMed Web of Science ®Google Scholar
• Walsh EE, Frenck RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 2020;383(25):2439–50. eng. doi:10.1056/NEJMoa2027906.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15. eng. doi:10.1056/NEJMoa2034577.
   PubMed Web of Science ®Google Scholar
• Vogel AB, Kanevsky I, Che Y, Swanson KA, Muik A, Vormehr M, Kranz LM, Walzer KC, Hein S, Güler A, et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature. 2021;592(7853):283–89. eng. doi:10.1038/s41586-021-03275-y.
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20. eng. doi:10.1056/NEJMoa1500596.
   PubMed Web of Science ®Google Scholar
• Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–13. eng. doi:10.1126/science.aan6733.
   PubMed Web of Science ®Google Scholar
• van den Bulk J, Verdegaal EME, Ruano D, Ijsselsteijn ME, Visser M, van der Breggen R, Duhen T, van der Ploeg M, de Vries NL, Oosting J, et al. Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4. Genome Med. 2019;11(1):87. eng. doi:10.1186/s13073-019-0697-8.
   PubMed Web of Science ®Google Scholar
• van den Bulk J, de Miranda NFCC, Ten Dijke P. Therapeutic targeting of TGF-β in cancer: hacking a master switch of immune suppression. Clin Sci (Lond). 2021;135(1):35–52. eng. doi:10.1042/CS20201236.
   PubMed Web of Science ®Google Scholar
• de Vries NL, van Unen V, Ijsselsteijn ME, Abdelaal T, van der Breggen R, Farina Sarasqueta A, Mahfouz A, Peeters KCMJ, Höllt T, Lelieveldt BPF, et al. High-dimensional cytometric analysis of colorectal cancer reveals novel mediators of antitumour immunity. Gut. 2020;69(4):691–703. eng. doi:10.1136/gutjnl-2019-318672.
   PubMed Web of Science ®Google Scholar
• Ohue Y, Nishikawa H. Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target? Cancer Sci. 2019;110(7):2080–89. eng. doi:10.1111/cas.14069.
   PubMed Web of Science ®Google Scholar
• Wang H, Franco F, Tsui Y-C, Xie X, Trefny MP, Zappasodi R, Mohmood SR, Fernández-García J, Tsai C-H, Schulze I, et al. CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors. Nat Immunol. 2020;21(3):298–308. eng. doi:10.1038/s41590-019-0589-5.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob -J-J, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345–56. eng. doi:10.1056/NEJMoa1709684.
   PubMed Web of Science ®Google Scholar
• Cabrita R, Lauss M, Sanna A, Donia M, Skaarup Larsen M, Mitra S, Johansson I, Phung B, Harbst K, Vallon-Christersson J, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020;577(7791):561–65. eng. doi:10.1073/pnas.091062498.
   PubMed Web of Science ®Google Scholar
• Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577(7791):549–55. eng. doi:10.1038/s41467-017-00608-2.
   PubMed Web of Science ®Google Scholar
• Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(6371):91–97. eng. doi:10.1126/science.aan3706.
   PubMed Web of Science ®Google Scholar
• Cascone T, William WN, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021;27(3):504–14. eng. doi:10.1093/nar/gks1219.
   PubMed Web of Science ®Google Scholar
• Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Lei YM, Jabri B, Alegre M-L, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350(6264):1084–89. eng. doi:10.1126/science.aac4255.
   PubMed Web of Science ®Google Scholar
• Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CPM, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350(6264):1079–84. eng. doi:10.1126/science.aad1329.
   PubMed Web of Science ®Google Scholar
• Davar D, Dzutsev AK, McCulloch JA, Rodrigues RR, Chauvin J-M, Morrison RM, Deblasio RN, Menna C, Ding Q, Pagliano O, et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 2021;371(6529):595–602. eng. doi:10.1126/science.abf3363.
   PubMed Web of Science ®Google Scholar
• Shaikh FY, White JR, Gills JJ, Hakozaki T, Richard C, Routy B, Okuma Y, Usyk M, Pandey A, Weber JS, et al. A uniform computational approach improved on existing pipelines to reveal microbiome biomarkers of nonresponse to immune checkpoint inhibitors. Clin Cancer Res. 2021;27(9):2571–83. eng. doi:10.1158/1078-0432.CCR-20-4834.
   PubMed Web of Science ®Google Scholar
• Welters MJP, Ma W, Santegoets SJAM, Goedemans R, Ehsan I, Jordanova ES, van Ham VJ, van Unen V, Koning F, van Egmond SI, et al. Intratumoral HPV16-specific T cells constitute a Type I-oriented tumor microenvironment to improve survival in HPV16-driven oropharyngeal cancer. Clin Cancer Res. 2018;24(3):634–47. eng. doi:10.1158/1078-0432.CCR-17-2140.
   PubMed Web of Science ®Google Scholar
• Acharya N, Madi A, Zhang H, Klapholz M, Escobar G, Dulberg S, Christian E, Ferreira M, Dixon KO, Fell G, et al. Endogenous glucocorticoid signaling regulates CD8+ T cell differentiation and development of dysfunction in the tumor microenvironment. Immunity. 2020;53(3):658–671.e6. eng. doi:10.1016/j.immuni.2020.08.005.
   PubMed Web of Science ®Google Scholar
• Marigo I, Trovato R, Hofer F, Ingangi V, Desantis G, Leone K, de Sanctis F, Ugel S, Canè S, Simonelli A, et al. Disabled homolog 2 controls prometastatic activity of tumor-associated macrophages. Cancer Discov. 2020;10(11):1758–73. eng. doi:10.1158/2159-8290.CD-20-0036.
   PubMed Web of Science ®Google Scholar
• Fiore A, Ugel S, de Sanctis F, Sandri S, Fracasso G, Trovato R, Sartoris S, Solito S, Mandruzzato S, Vascotto F, et al. Induction of immunosuppressive functions and NF-κB by FLIP in monocytes. Nat Commun. 2018;9(1):5193. eng. doi:10.1038/s41467-018-07654-4.
   PubMedGoogle Scholar
• Trovato R, Fiore A, Sartori S, Canè S, Giugno R, Cascione L, Paiella S, Salvia R, de Sanctis F, Poffe O, et al. Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3. J Immunother Cancer. 2019;7(1):255. eng. doi:10.1186/s40425-019-0734-6.
   PubMed Web of Science ®Google Scholar
• Bost P, de Sanctis F, Canè S, Ugel S, Donadello K, Castellucci M, Eyal D, Fiore A, Anselmi C, Barouni RM, et al. Deciphering the state of immune silence in fatal COVID-19 patients. Nat Commun. 2021;12(1):1428. eng. doi:10.1038/s41467-021-21702-6.
   PubMed Web of Science ®Google Scholar
• Bronte V, Ugel S, Tinazzi E, Vella A, de Sanctis F, Canè S, Batani V, Trovato R, Fiore A, Petrova V, et al. Baricitinib restrains the immune dysregulation in patients with severe COVID-19. J Clin Invest. 2020;130(12):6409–16. eng. doi:10.1172/JCI141772.
   PubMed Web of Science ®Google Scholar
• Jaitin DA, Kenigsberg E, Keren-Shaul H, Elefant N, Paul F, Zaretsky I, Mildner A, Cohen N, Jung S, Tanay A, et al. Massively parallel single-cell RNA-seq for marker-free decomposition of tissues into cell types. Science. 2014;343(6172):776–79. eng. doi:10.1126/science.1247651.
   PubMed Web of Science ®Google Scholar
• Giladi A, Cohen M, Medaglia C, Baran Y, Li B, Zada M, Bost P, Blecher-Gonen R, Salame T-M, Mayer JU, et al. Dissecting cellular crosstalk by sequencing physically interacting cells. Nat Biotechnol. 2020;38(5):629–37. eng. doi:10.1038/s41587-020-0442-2.
   PubMed Web of Science ®Google Scholar
• Katzenelenbogen Y, Sheban F, Yalin A, Yofe I, Svetlichnyy D, Jaitin DA, Bornstein C, Moshe A, Keren-Shaul H, Cohen M, et al. Coupled scRNA-Seq and intracellular protein activity reveal an immunosuppressive role of TREM2 in cancer. Cell. 2020;182(4):872–885.e19. eng. doi:10.1016/j.cell.2020.06.032.
   PubMed Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960–64. eng. doi:10.1126/science.1129139.
   PubMed Web of Science ®Google Scholar
• Angelova M, Charoentong P, Hackl H, Fischer ML, Snajder R, Krogsdam AM, Waldner MJ, Bindea G, Mlecnik B, Galon J, et al. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. Genome Biol. 2015;16:64. eng. doi:10.1186/s13059-015-0620-6.
   PubMed Web of Science ®Google Scholar
• Ott PA, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N, Margolin K, Awad MM, Hellmann MD, Lin JJ, et al. A Phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell. 2020;183(2):347–362.e24. eng. doi:10.1016/j.cell.2020.08.053.
   PubMed Web of Science ®Google Scholar
• Rubinsteyn A, Kodysh J, Hodes I, Mondet S, Aksoy BA, Finnigan JP, Bhardwaj N, Hammerbacher J. Computational pipeline for the PGV-001 neoantigen vaccine trial. Front Immunol. 2017;8:1807. eng. doi:10.3389/fimmu.2017.01807.
   PubMed Web of Science ®Google Scholar
• Belkadi A, Bolze A, Itan Y, Cobat A, Vincent QB, Antipenko A, Shang L, Boisson B, Casanova J-L, Abel L. Whole-genome sequencing is more powerful than whole-exome sequencing for detecting exome variants. Proc Natl Acad Sci U S A. 2015;112(17):5473–78. eng. doi:10.1073/pnas.1418631112.
   PubMed Web of Science ®Google Scholar
• McGranahan N, Swanton C. Neoantigen quality, not quantity. Sci Transl Med. 2019;11(506). eng. doi:10.1126/scitranslmed.aax7918.
   PubMed Web of Science ®Google Scholar
• Zhang J-Y, Yan -Y-Y, Li -J-J, Adhikari R, Fu L-W. PD-1/PD-L1 based combinational cancer therapy: icing on the cake. Front Pharmacol. 2020;11:722. eng. doi:10.3389/fphar.2020.00722.
   PubMed Web of Science ®Google Scholar
• Philip M, Fairchild L, Sun L, Horste EL, Camara S, Shakiba M, Scott AC, Viale A, Lauer P, Merghoub T, et al. Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature. 2017;545(7655):452–56. eng. doi:10.1038/nature22367.
   PubMed Web of Science ®Google Scholar
• Scott AC, Dündar F, Zumbo P, Chandran SS, Klebanoff CA, Shakiba M, Trivedi P, Menocal L, Appleby H, Camara S, et al. TOX is a critical regulator of tumour-specific T cell differentiation. Nature. 2019;571(7764):270–74. eng. doi:10.1038/s41586-019-1324-y.
   PubMed Web of Science ®Google Scholar
• Luo X, Li B, Zhang X, Zhao W, Bratasz A, Deng B, McComb DW, Dong Y. Dual-functional lipid-like nanoparticles for delivery of mRNA and MRI contrast agents. Nanoscale. 2017;9(4):1575–79. eng. doi:10.1039/c6nr08496f.
   PubMed Web of Science ®Google Scholar
• Momin N, Mehta NK, Bennett NR, Ma L, Palmeri JR, Chinn MM, Lutz EA, Kang B, Irvine DJ, Spranger S, et al. Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy. Sci Transl Med. 2019;11(498). eng. doi:10.1126/scitranslmed.aaw2614.
   PubMed Web of Science ®Google Scholar
• Zah E, Lin M-Y, Silva-Benedict A, Jensen MC, Chen YY. T cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells. Cancer Immunol Res. 2016;4(6):498–508. eng. doi:10.1158/2326-6066.CIR-15-0231.
   PubMed Web of Science ®Google Scholar
• Zah E, Nam E, Bhuvan V, Tran U, Ji BY, Gosliner SB, Wang X, Brown CE, Chen YY. Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma. Nat Commun. 2020;11(1):2283. eng. doi:10.1038/s41467-020-16160-5.
   PubMed Web of Science ®Google Scholar
• Chang ZL, Lorenzini MH, Chen X, Tran U, Bangayan NJ, Chen YY. Rewiring T-cell responses to soluble factors with chimeric antigen receptors. Nat Chem Biol. 2018;14(3):317–24. eng. doi:10.1038/nchembio.2565.
   PubMed Web of Science ®Google Scholar
• Hou AJ, Chang ZL, Lorenzini MH, Zah E, Chen YY. TGF-β-responsive CAR-T cells promote anti-tumor immune function. Bioeng Transl Med. 2018;3(2):75–86. eng. doi:10.1002/btm2.10097.
   PubMed Web of Science ®Google Scholar
• Chang ZL, Hou AJ, Chen YY. Engineering primary T cells with chimeric antigen receptors for rewired responses to soluble ligands. Nat Protoc. 2020;15(4):1507–24. eng. doi:10.1038/s41596-020-0294-8.
   PubMed Web of Science ®Google Scholar